Physician profile

Leigh A Dobbs

Physician Assistant · Bingham Farms, MI

NPI 1164492229

$250.17

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$250.17

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Corium, LLC $44.91 2023 Azstarys
Lundbeck LLC $42.52 2023 Rexulti
Abbvie INC. $38.12 2024
Tris Pharma INC $34.21 2023 Dyanavel Xr
Idorsia Pharmaceuticals US INC $19.85 2023 Quviviq
Teva Pharmaceuticals USA, INC. $18.85 2023 Austedo Xr
Takeda Pharmaceuticals U.S.A., INC. $18.26 2023 Trintellix
Janssen Pharmaceuticals, INC $17.00 2023 Spravato
Neurocrine Biosciences, INC. $16.45 2023 Ingrezza

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Leigh A Dobbs

$250.17

in general payments reported 2019-2025

Years
2023-2024
Top company
Corium, LLC

https://glasscript.com/doctor/10441663/leigh-a-dobbs

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.